Aadi Reduce Staff by 80% after Phase II Trial Fails

Following its decision to terminate the registrational Phase II PRECISION1 trial for nab-sirolimus, a mTOR inhibitor, Aadi Biosciences has implemented cost-cutting measures.

The Independent Data Monitoring Committee (IDMC) concluded that the trial “was unlikely to exceed an efficacy threshold necessary to support an accelerated approval,” which led the business to decide to cancel it.

Aadi also made the decision to stop recruiting for two other Phase II trials of nab-sirolimus for neuroendocrine tumours (NETs) and severe or persistent endometrioid-type endometrial cancer (EEC), respectively, at the same time.

Aadi is also cutting 80% of its personnel in research and development as part of the cost reduction plan. It is anticipated that the pipeline and labour restructuring would prolong Aadi’s cash runway into H2 2026. As of June 30, 2024, the corporation declared cash reserves of $78.6 million.

David Lennon, president and CEO of Aadi Bioscience stated: “While nab-sirolimus showed monotherapy activity in the study population, the trial fell short of delivering what we believe would be required to support an accelerated approval in the broad TSC1/TSC2 inactivating mutations indication. We look forward to providing the full trial analysis at a later date.”